Tirzepatide Fatigue: Causes, Fixes, and NAD+

The Short Answer

If you searched some version of "tirzepatide fatigue NAD" you have probably already seen the pitch: your cellular energy currency is depleted, the injection restores it, and the tiredness lifts. The pitch is tidy. The evidence behind it, for a person on a GLP-1 specifically, is empty. No trial has ever tested NAD+ for fatigue in people taking semaglutide or tirzepatide. No trial has combined NAD+ with either drug for any endpoint at all. That is the entire literature on the pairing, and it fits in two sentences.

Meanwhile, the fatigue itself usually has causes you can name and fix without a prescription. You are eating far less than your body is used to. The first weeks of weight loss drain glycogen, and glycogen leaves with several times its weight in water. Thirst signaling gets quieter on these medications, so mild dehydration sneaks in. Protein falls short because appetite suppression does not distinguish between chicken and chips. Sleep gets choppy for some people. And each dose increase restarts the adjustment clock. Every one of those produces the same complaint, and every one of them is cheaper to fix than a vial of anything.

So this page runs in what we would argue is the only defensible order. First, why the fatigue happens and when it typically fades. Second, the checklist to work through before any supplement enters the conversation. Third, what NAD+ actually is and what the human evidence does and does not show, including the awkward fact that the good trials used oral precursors rather than the injectable form. Fourth, how a prescribing clinic structures the pairing when it does get prescribed. NAD+ is the last item on this list on purpose. The sites selling it as the first item are answering a different question, which is how to sell NAD+.

Why GLP-1 Fatigue Happens

Fatigue shows up as a reported side effect across trials of the approved GLP-1 products, typically affecting a minority of participants, most often early in treatment and around dose increases. But the trial label "fatigue" flattens together several different physiological events, and telling them apart matters, because they have different fixes.

The deficit itself. These medications work by making you eat substantially less, and a body running on 40 percent fewer calories than it is adapted to has less fuel for everything, training and thinking included. Some tiredness in a deep deficit is not a malfunction. It is arithmetic. The question worth asking is not "why am I tired" but "how big is my deficit," because a deficit that is too aggressive produces exhaustion that no supplement addresses.

Glycogen and its water. The first weeks on a GLP-1 usually involve a sharp drop in carbohydrate intake. Your muscles and liver respond by running down glycogen, the stored form of carbohydrate, and every gram of glycogen is stored with roughly three grams of water. That is why early scale drops are so fast, and it is also why the first weeks can feel so flat: you are training and living on partially drained fuel tanks. This piece improves on its own as intake stabilizes, and it improves faster if some carbohydrate stays in the diet.

Dehydration and electrolytes. GLP-1 medications quiet appetite signaling broadly, and for many people that includes drinking less without noticing. Add the water lost with glycogen and, for some, nausea that discourages fluids, and mild chronic dehydration becomes one of the most common and least suspected causes of feeling terrible on these drugs. Headache plus fatigue plus dark urine is dehydration until proven otherwise.

The protein shortfall. Appetite suppression does not spare protein. Most people eating half their usual food are also eating half their usual protein, and a deficit raises the protein requirement rather than lowering it. Under-eating protein during rapid weight loss costs you lean tissue and contributes to the flat, weak feeling that gets attributed to the drug. Whether that lean loss is clinically dangerous is genuinely debated, and a 2024 JAMA viewpoint argued the alarm has outrun the data, but nobody debates that protein and resistance training are the levers that protect muscle. The full picture is in muscle loss on a GLP-1 Read nextHow to Keep Muscle While Taking Ozempic, Wegovy, or MounjaroUp to 40% of weight lost on GLP-1 medications is lean muscle. Here is what the research actually shows, why it happens, and which growth hormone peptides providers prescribe to preserve lean mass during a caloric deficit.Read article .

Conte C, Hall KD, Klein S. "Is Weight Loss-Induced Muscle Mass Loss Clinically Relevant?" JAMA, 2024. PMID 38829659. View study

Sleep disruption. Some people sleep worse during rapid weight loss: reflux from slowed gastric emptying if dinner runs late, more nighttime waking, or simply hunger-adjacent restlessness. Tired from a medication and tired from six hours of broken sleep feel identical from the inside. A week of tracking usually settles which one you have.

The dose-escalation window. A GLP-1 course opens with months of stepwise dose increases, and side effects cluster in the one to two weeks after each step. If your fatigue started within days of a dose change, the most likely explanation is the dose change, and the most likely outcome is that it fades as your body adjusts, the way it did after the previous step. For most people the overall pattern is early fatigue that eases substantially by the time the maintenance dose settles. If it is not fading, that is worth a conversation with the prescriber, which is what the dose review at each 28-day refill cycle is for.

The Checklist Before Any Supplement

Here is the same material as a working list. Run it honestly for two weeks. In our experience most GLP-1 fatigue resolves inside this table, which is exactly why pages selling an energy fix rarely print it.

Two of these deserve one more sentence each. The protein line is the one most people fail without knowing it, because nobody feels a protein shortfall the way they feel hunger; it just shows up as weakness and slow recovery, weeks later. And the calorie line matters because the medication will happily let you eat an amount that is genuinely too low. The drug removes the alarm bell. It does not remove the need for fuel.

What NAD+ Actually Is

Start with the category error that the marketing never corrects: NAD+ Explore PeRxNAD+The Cellular Energy CoenzymeView peptide is not a peptide. Nicotinamide adenine dinucleotide is a coenzyme, a small molecule that sits in every cell you have and shuttles electrons through the reactions that turn food into usable energy. It also feeds the sirtuin enzymes and the DNA-repair machinery. It ends up on peptide-clinic menus because the clinics that prescribe peptides also prescribe it, not because it belongs to the same chemical family. We sell it and we will still say that plainly.

The legitimate scientific core of the story is the age decline. Massudi and colleagues measured human tissue samples across age groups and documented that NAD+ levels fall with age while markers of oxidative stress rise. That finding is real, it has held up, and it is the reason "restore your NAD+" is such an effective pitch: the depletion half of the sentence is true. The leap is the second half, the assumption that topping the level back up produces felt energy, and that an injection is the way to do it. Those are two separate claims, and the evidence for each is where this gets interesting.

Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, Guillemin GJ. "Age-associated changes in oxidative stress and NAD+ metabolism in human tissue." PLoS One, 2012. PMID 22848760. View study

One more framing note before the evidence. "Low cellular energy" and "feeling tired on tirzepatide" are not the same thing, however similar they sound. The fatigue section above listed five causes, and none of them is an NAD+ deficiency. A 45-year-old in a 1,000-calorie deficit who is under-hydrated and under-slept has a fatigue problem that is fully explained without invoking coenzyme decline. That is why the checklist comes first, and it is also the fairest way to read everything below.

The Honest Evidence Map

What oral precursor trials showed

Nearly all of the credible human NAD+ research uses oral precursors, mostly nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), which the body converts to NAD+. The foundational safety result is Martens and colleagues: six weeks of oral NR in healthy middle-aged and older adults was well tolerated and raised blood NAD+ levels by roughly 60 percent. So repletion through the oral route is real and measurable. Notice what the endpoint was, though: the blood level, not energy, not fatigue, not performance.

Martens CR, Denman BA, Mazzo MR, et al. "Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults." Nat Commun, 2018. PMID 29599478. View study

The most relevant tissue-level result is Elhassan and colleagues, who gave oral NR to older adults and showed it changed the NAD+ metabolome of aged human skeletal muscle and dialed down some inflammatory signatures. That is a genuinely interesting finding, and it is the strongest human evidence that raising NAD+ availability does something measurable inside the tissue people care about. It still measured molecules, not how anyone felt.

Elhassan YS, Kluckova K, Fletcher RS, et al. "Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures." Cell Rep, 2019. PMID 31412242. View study

When trials chased functional endpoints, the results split. Dollerup and colleagues ran a 12-week randomized placebo-controlled trial of NR in obese, insulin-resistant men and found no improvement in insulin sensitivity or the other metabolic outcomes they measured. Yoshino and colleagues gave NMN to prediabetic women and did find improved muscle insulin sensitivity, a real positive, but a narrow one, in a specific population, with no fatigue or energy measure anywhere in the study. That is roughly the state of the art: repletion is achievable orally, tissue chemistry responds, and clinical benefits are inconsistent and modest where they appear at all.

Dollerup OL, Christensen B, Svart M, et al. "A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects." Am J Clin Nutr, 2018. PMID 29992272. View study

Yoshino M, Yoshino J, Kayser BD, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science, 2021. PMID 33888596. View study

What that means for the injectable form

Every study above used a capsule. PeRx ships NAD+ as a subcutaneous injection, and the injectable form does not inherit the oral trials. Injected NAD+ has its own pharmacology, its own absorption profile, and essentially no controlled trial literature of its own for energy, fatigue, or metabolic outcomes. The injection route is popular in clinics because it bypasses digestion and because an injection feels more serious than a capsule, not because a body of evidence chose it. If you have read our full NAD+ guide Read nextNAD+ Injection: The Complete Guide to the Longevity MoleculeHollywood's most talked-about anti-aging treatment used to require a $1,000 IV drip and four hours in a clinic. The same molecule, discovered in 1906, now comes as a simple at-home injection.Read article , this is the same evidence-status conclusion it reaches, applied to a more specific question.

And the more specific question makes the gap wider, not narrower. There is no study of NAD+ combined with semaglutide or tirzepatide, in any species, by any route. There is no trial of NAD+ for fatigue in people on a GLP-1. There is not even a trial of oral precursors in that population. Search PubMed and ClinicalTrials.gov for the combination and you get nothing as of August 2026. The stack exists because two products sit on the same clinic menu and because "restores cellular energy" slots neatly into the space that GLP-1 fatigue opens. That is menu logic, not evidence.

If your underlying interest is metabolic energy rather than fatigue relief specifically, two neighboring pages finish the picture: MOTS-c and semaglutide Read nextMOTS-c and Semaglutide: Can You Combine Them?Ask this question online and you get two kinds of answers. Retail sites say yes and quote fat-loss percentages that do not exist anywhere in the literature. Cautious sites say nothing has been studied and stop there. Both halves are doing part of the job. This page does the whole thing: what is actually known, including the analog trial almost nobody mentions, and how a prescribing clinic thinks about the combination in practice.Read article is the sibling deep dive on the other cellular-energy compound marketed to GLP-1 users, and MOTS-c vs NAD+ Read nextMOTS-c vs. NAD+: The Mitochondrial Energy DuoMOTS-c is a signal your mitochondria release during exercise. NAD+ is the coenzyme those mitochondria burn to make energy and run repair. People treat them as rivals because both live in the "cellular energy" conversation, but they sit at different points in the same system. This guide breaks down how each one works and which to consider first.Read article puts the two head to head. The short version is that both are mechanism stories waiting for human trials, and neither is a fatigue treatment.

How the Pairing Works in Practice

PeRx prescribes both compounds, so when a provider does decide the pairing makes sense, the logistics are concrete. Everything ships fully reconstituted and ready to use, with syringes and an injection guide in the box, and your PeRx provider will prescribe an optimal protocol based on your intake. What follows describes how the combination is typically structured, not a recommendation that you should be on it, and nothing here overrides the checklist above.

A few practical notes. There is no documented interaction between NAD+ and any GLP-1 receptor agonist; they act on unrelated systems, which is also why nothing about one changes the dosing of the other. Timing relative to the weekly GLP-1 dose does not matter, so most people simply keep NAD+ on its own weekday-morning rhythm. Site rotation is easy since the abdomen and thigh serve both products; the maps and the slow-injection technique that tames the NAD+ sting are in where to inject NAD+ Read nextWhere to Inject NAD+: Sites, Rotation, StingNAD+ is a subcutaneous injection, and it has a reputation for stinging more than most peptides. The good news is that the sting is almost entirely a technique problem. Where you put the needle, how slowly you push, and how you rotate all change the experience more than the molecule does. Here is the practical site-and-technique guide patients ask for after their first NAD+ vial arrives.Read article . And the evaluation window is not decoration. Decide in advance what NAD+ is supposed to change for you, in writing if you have to, because you will be adapting to the GLP-1 and probably sleeping and eating better at the same time, and everything improving at once is exactly the condition under which people credit the wrong intervention.

Who Should Skip It

Common Questions